{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:08:39Z","timestamp":1790878119667,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"3pt2","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Between October 2013 and March 2014, French Polynesia experienced the largest Zika virus (ZIKV) outbreak ever described before the emergence of ZIKV in the Americas in 2015. As arbovirus transfusion\u2010transmitted (TT) infections have been previously reported, we hypothesized that transfusion of blood products could also transmit ZIKV.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Mitigation strategies to prevent ZIKV\u2010TT infections included nonspecific measures and the implementation of a laboratory developed ZIKV\u2010specific nucleic acid testing (NAT) assay. Donor sera were tested in pools of 3 and constitutive sera of ZIKV\u2010reactive pools were tested individually. Donor sera were tested prospectively and retrospectively. A posttransfusion follow\u2010up of a patient transfused with ZIKV RNA\u2013reactive blood products was implemented.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>NAT detected 42 blood donor sera as ZIKV RNA reactive of 1505 tested (2.8%). Thirty ZIKV RNA\u2013reactive blood products collected before the implementation of NAT were transfused to 26 recipients. Posttransfusion investigations were conducted by the hemovigilance unit and data were available for 12 recipients. Symptomatic ZIKV\u2010TT infections were not reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Predonation screening of blood donors, postdonation information, products discard, and quarantine of blood products were not effective enough to prevent transfusion of ZIKV RNA\u2013reactive blood products. ZIKV NAT was an effective measure once implemented to prevent transfusion of ZIKV RNA\u2013reactive blood products but it is difficult to evaluate the effectiveness of this measure to prevent ZIKV\u2010TT infection, which is a rare event.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14028","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T06:02:45Z","timestamp":1486706565000},"page":"729-733","source":"Crossref","is-referenced-by-count":33,"title":["Zika virus and blood transfusion: the experience of French Polynesia"],"prefix":"10.1111","volume":"57","author":[{"given":"Damien","family":"Bierlaire","sequence":"first","affiliation":[{"name":"Hemovigilance Unit Tahiti French Polynesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Mauguin","sequence":"additional","affiliation":[{"name":"Hemovigilance Unit Tahiti French Polynesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Broult","sequence":"additional","affiliation":[{"name":"French Polynesian Blood Bank H\u00f4pital du Taaone Tahiti French Polynesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Musso","sequence":"additional","affiliation":[{"name":"Unit of Emerging Infectious Diseases Institut Louis Malard\u00e9 Tahiti French Polynesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(52)90042-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00072-15"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805715"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1408.080287"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00562-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2011.141380"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044333"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03269.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01522"},{"key":"e_1_2_8_11_1","first-page":"34","article-title":"Transfusion\u2010related transmission of yellow fever vaccine virus\u2014California, 2009","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323937"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.14.20761"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13271"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.10.005"},{"key":"e_1_2_8_16_1","volume-title":"Blood Products Advisory Committee Meeting Transcript [Internet]","author":"US Food and Drug Administration","year":"2010"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13677"},{"key":"e_1_2_8_18_1","unstructured":"European Centre for Disease Prevention and Control. Zika virus infection outbreak French Polynesia [Internet]. Stockholm: ECDC; 14 Feb 2014 [cited 2017 Jan 22]. Available from:http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Zika-virus-French-Polynesia-rapid-risk-assessment.pdf."},{"key":"e_1_2_8_19_1","first-page":"1","article-title":"Zika virus: new emergencies, potential for severe complications, and prevention of transfusion\u2010transmitted Zika fever in the context of arboviruses co\u2010circulation","volume":"28","author":"Musso D","year":"2016","journal-title":"Blood Transfus"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6530e1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13681"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1607262"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12713"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v5i1.363"},{"key":"e_1_2_8_25_1","volume-title":"Maintaining a safe and adequate blood supply during Zika virus outbreaks [Internet]","author":"World Health Organization","year":"2016"},{"key":"e_1_2_8_26_1","volume-title":"Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components [Internet]","author":"US Food and Drug Administration","year":"2016"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30428-7"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:36:28Z","timestamp":1694626588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":26,"journal-issue":{"issue":"3pt2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/trf.14028"],"URL":"https:\/\/doi.org\/10.1111\/trf.14028","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]}}}